[{"id":"a4644e4f-7f77-41bb-aff1-11853d753688","acronym":"","url":"https://clinicaltrials.gov/study/NCT01617668","created_at":"2021-01-18T06:55:54.569Z","updated_at":"2024-07-02T16:37:28.440Z","phase":"Phase 2","brief_title":"A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT01617668","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • LCL161"],"overall_status":"Completed","enrollment":" Enrollment 209","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 09/01/2014","study_completion_date":" 09/01/2014","last_update_posted":"2016-10-17"}]